Actavis is one of the world´s leading players in the development, manufacture, and sale of first-class generic pharmaceuticals. Founded in 1956, the Group has approximately 10,000 employees operating in more than 40 countries around the globe. As one of the fastest growing companies in the sector, Between 1999 and 2008, Actavis transformed itself from an exclusively Icelandic pharmaceutical company with 146 employees and EUR 57m in revenues to the global number five generics player with an operating presence in 40 countries, 10,000 employees and generating EUR 1.7bn in revenues. Actavis is committed to providing its customers with a wide range of affordable, high-quality products covering all significant therapeutic areas. The group has 830 products on the markets and about 400 new projects in the pipeline, presence in five continents and production at 16 manufacturing facilities for pharmaceutical products in 13 different countries.
The NLFÍ offers three kinds of treatment: Preventative, psychological/phyiscal and skeletal (or bone). Within these three categories, nine treatment options are offered. These address geriatric disorders; obesity problems; chronic aches; arthritis, heart, and cancer conditions; psychological and stress ailments; handicaps (mainly acquired); and post surgery joint problems (hip and knee replacements). More than 2,000 patients are treated at the NLFÍ Clinic annually.